DBV Technologies SA (DBVT)
0.5898
+0.03
(+5.32%)
USD |
NASDAQ |
Nov 15, 16:00
0.56
-0.03
(-5.05%)
After-Hours: 20:00
DBV Technologies Research and Development Expense (TTM): 83.21M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 83.21M |
| June 30, 2024 | 73.35M |
| March 31, 2024 | 65.59M |
| December 31, 2023 | 60.22M |
| September 30, 2023 | 77.06M |
| June 30, 2023 | 78.36M |
| March 31, 2023 | 79.36M |
| December 31, 2022 | 75.54M |
| September 30, 2022 | 57.60M |
| June 30, 2022 | 58.83M |
| Date | Value |
|---|---|
| March 31, 2022 | 60.40M |
| December 31, 2021 | 70.34M |
| September 30, 2021 | 85.06M |
| June 30, 2021 | 94.49M |
| March 31, 2021 | 96.24M |
| December 31, 2020 | 101.61M |
| September 30, 2020 | 109.71M |
| June 30, 2020 | 105.17M |
| March 31, 2020 | 116.50M |
| December 31, 2019 | 120.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
57.60M
Minimum
Sep 2022
120.55M
Maximum
Dec 2019
83.46M
Average
78.86M
Median
Research and Development Expense (TTM) Benchmarks
| Edap TMS SA | 8.741M |
| Cellectis SA | 94.63M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 143.17M |
| Akari Therapeutics PLC | 8.848M |